InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.00.

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of InflaRx in a research note on Tuesday, April 21st. HC Wainwright lifted their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, Oppenheimer started coverage on shares of InflaRx in a research note on Friday, April 24th. They set an “outperform” rating and a $5.00 price objective for the company.

InflaRx Stock Up 3.0%

IFRX opened at $2.44 on Friday. The company has a market capitalization of $176.39 million, a price-to-earnings ratio of -3.44 and a beta of 2.42. The firm has a 50-day moving average price of $1.47 and a 200-day moving average price of $1.20. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, sell-side analysts expect that InflaRx will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently bought and sold shares of IFRX. Bank of America Corp DE purchased a new position in InflaRx during the third quarter valued at approximately $3,316,000. Suvretta Capital Management LLC grew its stake in InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares in the last quarter. 683 Capital Management LLC grew its stake in InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after acquiring an additional 1,065,000 shares in the last quarter. Woodline Partners LP purchased a new position in InflaRx during the first quarter valued at approximately $766,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in InflaRx during the second quarter valued at approximately $262,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.